Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEGF expression during neoadjuvant chemoradiation for esophageal carcinoma
NL-OMON23950Recruiting
- Sponsor
- VU University Medical Centre, Amsterdam, The Netherlands
- Start
- Feb 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of bevacizumab in esophageal cancer (2 arms), sponsored by VU University Medical Centre, Amsterdam, The Netherlands. Primary endpoints: Change in tumor VEGF mRNA expression, VEGFR phosphorylation activity in bevacizumab cohort and 1 more. Started Feb 2014; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NL-OMON23950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23950.